drugset / Trial / NCT00086710
Study of Enfuvirtide in HIV-Positive Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enfuvirtide | Peptide | 90 mg | Subcutaneous |